Treating previously untreatable cancers: How CAR-T cell therapy could be made accessible to more patients
This image was generated by AI and may not depict real events.
CAR-T cell therapy, a treatment for previously untreatable cancers, is being made more accessible to patients in Canada through non-commercial academic research. Canadian researchers are developing affordable CAR-T therapies with comparable clinical outcomes to reduce costs and improve accessibility.
CAR-T cell therapy is a treatment for previously untreatable cancers. It modifies a patient's T cells to recognize and attack cancer cells. The therapy is currently expensive and complex, with a centralized model that takes four to six weeks to produce. Canadian academic researchers are developing non-commercial CAR-T therapies to improve accessibility. These therapies are being developed by public institutions and are undergoing clinical trials. The goal is to reduce costs while keeping comparable clinical outcomes, making the treatment more accessible to patients.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.